Format

Send to

Choose Destination
PLoS One. 2016 Apr 19;11(4):e0152618. doi: 10.1371/journal.pone.0152618. eCollection 2016.

Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.

Author information

1
Health Outcomes, GlaxoSmithKline, Uxbridge, United Kingdom.
2
GlaxoSmithKline, Real World Evidence, Uxbridge, United Kingdom.
3
University of Ulsan College of Medicine, Asan Medical Centre, Seoul, South Korea.
4
University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
5
Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, Michigan, United States of America.
6
University of Kentucky College of Public Health, Lexington, Kentucky, United States of America.
7
Tohoku University Graduate School of Medicine, Sendai, Japan.
8
GlaxoSmithKline, Value Evidence Outcomes, Uxbridge, United Kingdom.

Abstract

BACKGROUND:

The Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.

METHODS:

This cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.

RESULTS:

The annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.

CONCLUSIONS:

The economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

PMID:
27092775
PMCID:
PMC4836731
DOI:
10.1371/journal.pone.0152618
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center